Out with the old, in with the new. What worked for small molecules and MAbs is irrelevant. We co-hosted this webinar with Impatient to help the audience uncover strategic frameworks, tailored for ATMP access challenges.
Inbeeo’s team, including Sara, John, Konstantina, and Yigit, is at ISPOR Europe 2022 in Vienna. They are eager to connect with fellow market access and HEOR professionals to discuss HTA, pricing, and market access through their poster presentations.
Affordable cancer medicines alone don’t ensure timely, appropriate treatment. Availability in developed markets raises questions about industry efforts for access in LLMICs
All eyes were on pharma biotech companies in 2020, as they raced against each other to find solutions to alleviate the Covid-19 pandemic through vaccines and treatments.
Some initial market access decisions, made during a unique healthcare crisis, hint at lasting changes for pharmaceutical market access.
The Health Foundation and ICHOM are among the many stakeholders calling for an evolution of how we look at value in healthcare. Here are four trends emerging from their pledge.
Five tips worth keeping mind when planning for market access. An infographic.
I have learned the hard way that defining the value of a pharmaceutical innovation is not as easy as “Bob’s your uncle”.
Whatever happens next in the US and elsewhere, life science companies must take charge and own the value story behind their innovative products. It starts by understanding and mastering value assessment frameworks. An Inbeeo thought experiment.
Making sure your new product brings no bad budgetary news, clearly telling its value story, and pricing it fairly will help you convince your payer audience to fund it.
